Search Results

The Jeb E. Brooks School of Public Policy at Cornell University recently announced the launch of its new Biotech and Pharmaceutical Management Program aimed at preparing the next generation of leaders in the rapidly evolving biotechnology and pharmaceutical fields.

Dr. Robert A. Harrington, a cardiologist and the Arthur L. Bloomfield Professor of Medicine and chair of the Department of Medicine at Stanford University, has been named the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University.

Applied DNA Sciences, Inc. and the Cornell University College of Veterinary Medicine announced the signing of a sponsored research agreement for a translational research study to accelerate the development and optimization of the Company’s LineaDNA™-lipid nano particle -based veterinary vaccine platform for veterinary diseases.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.

Applied DNA Sciences, Inc., a leader in polymerase chain reaction -based technologies, and the Cornell University College of Veterinary Medicine announced the signing of a research agreement to advance LinearDNA™-based vaccine research and discovery for animal diseases with agricultural biosecurity implications.